Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cereno Scientific (XSAT: CRNO B) today announced that the company will participate at multiple upcoming investor conferences where CEO Sten R. Sörensen will present progress of clinical and preclinical development programs and future outlook.
ABG Sundal Collier Life Science Summit (virtual)
Date/time: May 19, 2022, 8.30-9.00 CET
Presenter: CEO Sten R. Sörensen
Registration to attend: Please contact your ABGSC contact person
Redeye Growth Day 2022 (hybrid)
Date/time: June 2, 2022, 8.40-9.00 CET
Presenter: Presentation by CEO Sten R. Sörensen (virtual), Q&A by CMO Björn Dahlöf (onsite)
Registration to attend: https://www.redeye.se/events/833514/redeye-growth-day-2022
BioStock Life Science Spring Summit 2022 (virtual)
Date/time: June 8-9, 2022
Presenter: CEO Sten R. Sörensen
Registration to attend: https://www.biostock.se/en/2022/04/biostock-life-science-spring-summit-june-8-9/
Aktiespararna's Småbolagsdagarna 2022 (hybrid)
Date/time: June 14, 2022, 13.30-14.00 CET
Presenter: CEO Sten R. Sörensen (onsite)
Registration to attend: https://www.aktiespararna.se/smabolagsdagarna
A recording of the each presentation will be made available on Cereno's website, www.cerenoscientific.com, when possible.
Capital Markets Day
Following positive response from Cereno's first webcast in March 2022 focused on the Phase II study of lead drug candidate CS1, Cereno is planning a Capital Markets Day that will take place in the beginning of fall. More information about this event will follow.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Targeted at treating cardiovascular disease, drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist and drug candidate CS014 is an HDAC inhibitor with epigenetic effects. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.